BioPharma Resources

Drug Trial Radar · NCT03005782

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

333

Actual

Start

Nov 7, 2016

Primary completion

Apr 2, 2024

Study completion Apr 2, 2024

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Dec 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).

Conditions

  • Malignancies

Interventions

  • REGN3767Drug

  • cemiplimabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dose limiting toxicities (Dose Escalation Phase)Time frame: Baseline to 28 days
  2. Rate of adverse events (Dose Escalation Phase)Time frame: Baseline to 51 weeks
  3. Rate of serious adverse events (Dose Escalation Phase)Time frame: Baseline to 51 weeks
  4. Occurrence of death (Dose Escalation Phase)Time frame: Baseline to 51 weeks
  5. Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Escalation Phase)Time frame: Baseline to 51 weeks
  6. Area under the curve (AUC) computed from time zero to the time of the last concentration [AUCall] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  7. AUCall-to-dose ratio [AUCall/Dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  8. AUC from time zero extrapolated to infinity [AUCinf] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  9. AUCinf-to-dose ratio [AUCinf/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  10. AUC computed from time zero to the time of the last positive concentration [AUClast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  11. AUClast-to-dose ratio [AUClast/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  12. Clearance [CL] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  13. Maximum Plasma Concentration [Cmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to week 51
  14. Cmax-to-dose ratio [Cmax/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  15. Last positive (quantifiable) concentration [Clast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  16. Mean residence time extrapolated to infinity [MRTinf] (Dose Escalation Phase)Time frame: Baseline to 51 weeks
  17. Mean residence time when the drug concentration profile is based on values up to and including the last positive concentration [MRTlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  18. Observed terminal half-life [t1/2] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  19. t1/2 beta (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  20. Time of the last positive (quantifiable) concentration [tlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  21. Time to Cmax [tmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  22. Volume of distribution at steady state [Vss] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  23. Volume of distribution of the terminal phase [Vz] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
  24. Objective response rate based on RECIST 1.1 for Solid Tumors (Dose Expansion phase)Time frame: Baseline to 51 weeks
  25. Objective response rate by Lugano criteria for Lymphoma (Dose Expansion Phase)Time frame: Baseline to 51 weeks

Locations

43 sites in 5 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research and Excellence

    Encinitas, California

  • California Cancer Associates For Research And Excellence

    Fresno, California

  • University of California San Diego (UCSD)

    La Jolla, California

  • The Angeles Clinic

    Los Angeles, California

  • University of California Davis Health Systems

    Sacramento, California

  • California Pacific Medical Center (CPMC)

    San Francisco, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Miami Cancer Institute

    Miami, Florida

  • Orlando Health, Inc

    Orlando, Florida

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • University of Kansas Clinical Research Center

    Fairway, Kansas

  • Dana Farber Cancer Institute

    Jamaica Plain, Massachusetts

  • Henry Ford Health Hospital

    Detroit, Michigan

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Washington University in Saint Louis

    St Louis, Missouri

  • John Theurer Cancer Center, Hackensack University Medical Center

    Hackensack, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • New Mexico Cancer Care Alliance-UNM Cancer Center

    Albuquerque, New Mexico

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Northwell Health-Monter Cancer Center

    Lake Success, New York

  • Laura & Isaac Perlmutter Cancer Center

    New York, New York

  • Columbia University

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • University Hospitals Seidman Cancer Center and Case Western Reserve University

    Cleveland, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Rhode Island Hospital

    Providence, Rhode Island

  • Hollings Cancer Center - Medical University of South Carolina

    Charleston, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • South Texas Oncology and Hematology

    San Antonio, Texas

  • Virginia Cancer Care Specialist, PC

    Fairfax, Virginia

  • Royal Brisbane and Women's Hospital

    Brisbane, Australia

  • Peter Maccallum Cancer Centre (PMCC)

    Melbourne, Australia

  • The University of Western Australia - The Queen Elizabeth II Medical Centre (QEIIMC) - Sir Charles Gairdner Hospital (SCGH)

    Perth, Western Australia, Australia

  • St. Vincents University Hospital

    Dublin, Ireland

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.